Float Short %

13.49

Margin Of Safety %

Put/Call OI Ratio

0.16

EPS Next Q Diff

-0.01

EPS Last/This Y

EPS This/Next Y

-0.08

Price

47.38

Target Price

87.22

Analyst Recom

Performance Q

Relative Volume

0.99

Beta

1.18

Ticker: MRUS

21 items of 1

Date	Symbol	Last	P/C OI	P/C Vol	Total OI
2025-01-23	MRUS	41.1	0.20	0.50	6660
2025-01-24	MRUS	41.35	0.20	0.22	6661
2025-01-27	MRUS	40.43	0.20	0.08	6668
2025-01-28	MRUS	40.76	0.20	0.00	6700
2025-01-29	MRUS	41.67	0.20	0.00	6724
2025-01-30	MRUS	41.56	0.20	0.02	6724
2025-01-31	MRUS	41.01	0.20	0.20	6697
2025-02-03	MRUS	39.62	0.20	0.03	6698
2025-02-04	MRUS	40.49	0.20	0.57	6780
2025-02-05	MRUS	41.65	0.20	0.02	6771
2025-02-06	MRUS	41.54	0.21	0.08	6754
2025-02-07	MRUS	41.31	0.21	0.17	6769
2025-02-10	MRUS	40.65	0.21	0.20	6774
2025-02-11	MRUS	40.16	0.21	1.57	6778
2025-02-12	MRUS	40.29	0.21	1.33	6788
2025-02-13	MRUS	40.27	0.21	0.08	6794
2025-02-14	MRUS	40.11	0.21	0.03	6816
2025-02-18	MRUS	42.27	0.17	0.11	6598
2025-02-19	MRUS	45.03	0.18	0.00	6999
2025-02-20	MRUS	47.64	0.17	0.01	7546
2025-02-21	MRUS	47.43	0.16	26.56	7888
Date	Symbol	Last	P/C OI	P/C Vol	Total OI

21 items 1 of 1

21 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2025-01-23	MRUS	41.11	13.5	-94.2	-3.75
2025-01-24	MRUS	41.35	13.5	-91.8	-3.75
2025-01-27	MRUS	40.33	13.5	-79.7	-3.75
2025-01-28	MRUS	40.72	13.5	-92.6	-3.75
2025-01-29	MRUS	41.62	13.5	-98.7	-3.75
2025-01-30	MRUS	41.57	13.5	-88.6	-3.75
2025-01-31	MRUS	40.94	13.5	-83.3	-3.75
2025-02-03	MRUS	39.61	13.5	-76.0	-3.75
2025-02-04	MRUS	40.57	13.5	-99.4	-3.75
2025-02-05	MRUS	41.63	13.5	-99.0	-3.75
2025-02-06	MRUS	41.59	13.5	-88.8	-3.75
2025-02-07	MRUS	41.35	13.5	-87.5	-3.75
2025-02-10	MRUS	40.64	13.5	-83.4	-3.75
2025-02-11	MRUS	40.13	13.5	-84.2	-3.75
2025-02-12	MRUS	40.31	13.5	-91.5	-3.75
2025-02-13	MRUS	40.30	13.5	-89.8	-3.75
2025-02-14	MRUS	40.20	13.5	-88.4	-3.75
2025-02-18	MRUS	42.24	17.2	-110.4	-3.75
2025-02-19	MRUS	45.07	17.2	-116.3	-3.75
2025-02-20	MRUS	47.56	17.2	-111.5	-3.75
2025-02-21	MRUS	47.38	17.2	-87.3	-3.75
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

21 items 1 of 1

21 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2025-01-23	MRUS	-0.05	4.87	14.09
2025-01-24	MRUS	-0.05	4.87	14.09
2025-01-27	MRUS	-0.05	4.88	14.09
2025-01-28	MRUS	-0.05	4.88	13.66
2025-01-29	MRUS	-0.05	4.88	13.66
2025-01-30	MRUS	-0.05	4.88	13.66
2025-01-31	MRUS	-0.05	4.88	13.66
2025-02-03	MRUS	-0.05	4.78	13.66
2025-02-04	MRUS	-0.05	4.78	13.66
2025-02-05	MRUS	-0.05	4.78	13.66
2025-02-06	MRUS	-0.05	4.78	13.66
2025-02-07	MRUS	-0.05	4.78	13.66
2025-02-10	MRUS	-0.05	4.96	13.66
2025-02-11	MRUS	-0.05	4.96	13.66
2025-02-12	MRUS	-0.05	4.96	13.11
2025-02-13	MRUS	-0.05	4.96	13.11
2025-02-14	MRUS	-0.05	4.96	13.11
2025-02-18	MRUS	-0.05	3.41	13.49
2025-02-19	MRUS	-0.04	3.41	13.49
2025-02-20	MRUS	-0.04	3.41	13.49
2025-02-21	MRUS	-0.04	3.41	13.49
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

21 items 1 of 1

Last Quarter Act. EPS

-0.95

Avg. EPS Est. Current Quarter

-0.94

Avg. EPS Est. Next Quarter

-0.96

Insider Transactions

-0.04

Institutional Transactions

3.41

Beta

1.18

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

23.1

Max Drawdown 5-Year %

-60.4

Target Price

87.22

P/E

Forward P/E

PEG

P/S

90.26

P/B

4.61

P/Free Cash Flow

EPS

-3.91

Average EPS Est. Cur. Y

-3.75

EPS Next Y. (Est.)

-3.83

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-680.61

Relative Volume

0.99

Return on Equity vs Sector %

-54

Return on Equity vs Industry %

-38.4

EPS 1 7Days Diff

EPS 1 30Days Diff

0.02

EBIT Estimation

-87.3

Merus N.V.

Sector: Healthcare

Industry: Biotechnology

Employees: 172

Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1. The company is also developing MCLA-158, which is in a phase I clinical trial for the treatment of solid tumors; MCLA-145, which is in phase 1 clinical trials for the treatment of solid tumors; MCLA-129, which is in phase 1/2 clinical trials for the treatment of patients with advanced non-small cell lung cancer and other solid tumors; and ONO-4685 that is Phase 1 clinical trial to treat relapsed/refractory T cell lymphoma. In addition, it has collaboration agreement with Betta Pharmaceuticals Co. Ltd for the research and development of stage bispecific antibody candidates include MCLA-129; collaboration with Incyte Corporation for the development of MCLA-145; and collaboration with Gilead Sciences, Inc. to discover novel antibody-based trispecific T-cell engagers. The company was incorporated in 2003 and is headquartered in Utrecht, the Netherlands.

stock quote shares MRUS – Merus N.V Stock Price stock today

news today MRUS – Merus N.V stock forecast ,stock prediction 2023 2024 2025

marketwatch MRUS – Merus N.V yahoo finance google finance

stock history MRUS – Merus N.V invest stock market

stock prices MRUS premarket after hours

ticker MRUS fair value insiders trading

Investment involves risk. As a general rule, you should only trade in financial products that you are familiar with and understand the risk associated with them. The risk warning described in each financial product below is not exhaustive, you should carefully consider your investment experience, financial situation, investment objective, risk tolerance level and consult your independent financial adviser as to the suitability of your situation prior making any investment.

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Relative Volume

Beta

Ticker: MRUS

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

P/B

P/Free Cash Flow

EPS

Average EPS Est. Cur. Y​

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

Return on Equity vs Sector %

Return on Equity vs Industry %

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Get Started

About

Last Quarter Act. EPS

Average EPS Est. Cur. Y